Skip to main content

Nihon Medi-Physics Co., Ltd.

Contributing to medical care as a leading radiopharmaceutical firm.

  • Site Map
  • Japanese
Enter the terms you wish to search for.
  • Home
  • Company Profile
    • Top Message
    • Vision and Management Policy
    • Overview
    • History
    • Locations of Offices and Facilities
  • Our Business
    • Business fields
    • For optimal use of our product
    • Product supply system
    • Research and Development
    • Non-clinical PET molecular imaging business
  • Our Products
  • For Recognition of Nuclear Medicine
    • Conferences / Exhibitions
    • Collaboration with academic societies
    • Technical workshop by Imaging Information Technology Center
    • Wagner-Torizuka Fellowship

Press Release

  1. Home
  2. Press Release
June 15, 2020
Nihon Medi-Physics and Global Medical Solutions Announce Strategic Partnership in Nuclear Medicine Markets in Asia and Oceania
ENG_20200615_Press Release_GMS.pdf841.44 KB
October 11, 2019
Nihon Medi-Physics Accelerates “Theranostics” Development
Press Release_191011_Theranostics.pdf458.74 KB
October 11, 2019
Nihon Medi-Physics Launches In-house Production of Molybdenum-99
Press Release_191011Molybdenum-99.pdf262.55 KB
July 3, 2019
Nihon Medi-Physics and Combinostics Enter into an Exclusive Agreement to Develop and Market Software Diagnosing Dementia
20190703.pdf610.71 KB
June 25, 2019
DuChemBio and Nihon Medi-Physics sign joint Development and Distribution Agreement to Develop and Commercialize FACBC
20190625.pdf720.06 KB
March 26, 2019
Nihon Medi-Physics' Strategic Move for Contribution to Cancer Treatment
20190326.pdf578.87 KB
January 18, 2019
Nihon Medi-Physics & Yantai Dongcheng Pharmaceutical Group Announce Strategic Partnership for Enhancing Presence in Chinese Nuclear Medicine Market
20190118.pdf579.64 KB
December 18, 2018
PeptiDream & Nihon Medi-Physics Announce Strategic Alliance for the Discovery & Development of Peptide-based Theranostics
20181218.pdf156.8 KB
December 17, 2018
Nihon Medi-Physics Co., Ltd and Norwegian Startup Mentis Cura AS Enter into an Exclusive Agreement to Accelerate Clinical Development of Mentis Cura AS's Proprietary AI-based Software as Novel Dementia Diagnosis EEG Bbiomarker in Japan
20181217.pdf145.35 KB
November 29, 2018
Telix and Nihon Medi-Physics to Collaborate on Actinium Renal Cancer Therapeutics
20181129.pdf94.14 KB

Pagination

  • Current page 1
  • Page 2
  • Next page ›
  • Last page Last »

Nihon Medi-Physics Co., Ltd. logo

About the contents of this website

Product information in this Website is provided to offer general information on the Company’s pharmaceutical products. It is not intended to provide medical advice or usage descriptions of the Company’s pharmaceutical products. This Website is not to be used as an alternative for medical practitioners such as physicians and pharmacists to consult with patients in order to determine medical treatments. In addition, the information about the products (including products under development) on this Website does not constitute a promotion or commercial advertisement of the product or its efficacy.

Product information provided on this Website is intended for medical practitioners for use in Japan, and the contents therein are based on approvals that have been granted in Japan. If you are accessing this Website from outside of Japan, please be aware that the product information available on this Website might not be appropriate for you. Please confirm the approval status and content in your relevant country.

Do you agree?
YES
NO
  • About Our Site

Copyright © Nihon Medi-Physics Co.,Ltd. All Rights Reserved.

このページの先頭へ